Central corticotropin-releasing factor (CRF) may attenuate somatic pain sensitivity through involvement of glucocorticoids

Journal of Physiology and Pharmacology

Volumn 62, Issue 5, 2011, Pages 541-548

  Yarushkina, N I ^a   Bagaeva, T R ^a   Filaretova, L P ^a  

^a PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

Author keywords

Analgesia; Corticotropin releasing factor; Glucocorticoid receptors; Glucocorticoids; Opioid receptors; Somatic pain sensitivity

Indexed keywords

BETA ENDORPHIN; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; NALTREXONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; ELECTRIC CURRENT; HORMONE ACTION; HYPOPHYSIS FUNCTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NOCICEPTION; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; RAT;

ANALGESICS, NON-NARCOTIC; ANIMALS; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; ELECTRIC STIMULATION; GLUCOCORTICOIDS; INJECTIONS, INTRAVENTRICULAR; MALE; MIFEPRISTONE; NALTREXONE; NOCICEPTIVE PAIN; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; RECEPTORS, OPIOID;

EID: 84855743814     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Papadimitriou A, Priftis KN. Regulation of the hypothalamicpituitary- adrenal axis. Neuroimmunomodulation 2009; 16: 265-271.
2. Zelena D, Barna I, Mlynarik M, Gupta OP, Jezova D, Makara GB. Stress symptoms induced by repeated morphine withdrawal in comparison to other chronic stress models in mice. Neuroendocrinology 2005; 81: 205-215.
3. Larauche M, Kiank C, Tache Y. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol 2009; 60(Suppl. 7): 33-46.
4. Ohmura Y, Yoshioka MM. The roles of corticotropin releasing factor (CRF) in responses to emotional stress: is CRF release a cause or result of fear/anxiety? CNS Neurol Disord Drug Targets 2009; 8: 459-469.
5. Butler RK, Finn DP. Stress-induced analgesia. Prog Neurobiol 2009; 88; 184-202.
6. Filaretov AA, Bogdanov AI, Yarushkina NI. Stress-induced analgesia. The role of hormones produced by the hypophyseal-adrenocortical system. Neurosci Behav Physiol 1996; 26: 572-578.
7. Schafer M, Mousa SA, Zhang Q, Carter L, Stein C. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad Sci USA 1996; 93: 6096-6100.
8. Likar R, Mousa SA, Steinkellner H, et al. Involvement of intra-articular corticotropin- releasing hormone in postoperative pain modulation. Clin J Pain 2007; 23: 136-142.
9. Mousa SA, Bopaiah CP, Stein C, Schafer M. Involvement of corticotropin-releasing hormone receptor subtypes 1 and 2 in peripheral opioid-mediated inhibition of inflammatory pain. Pain 2003; 106: 297-307.
10. Sinniger V, Porcher C, Mouchet P, Juhem A, Bonaz B. C-fos and CRF receptor gene transcription in the brain of acetic acid induced somato-visceral pain in rats. Pain 2004; 110: 738-750.
11. Gyires K, Zadori ZS, Racz B, Laszlo J. Pharmacological analysis of inhomogeneous static magnetic field-induced antinociceptive action in the mouse. Bioelectromagnetics 2008; 29: 456-462.
12. Laszlo J, Timar J, Gyarmati Z, Furst Z, Gyires K. Paininhibiting inhomogeneous static magnetic field fails to influence locomotor activity and anxiety behavior in mice: no interference between magnetic field- and morphinetreatment. Brain Res Bull 2009; 79: 316-321.
13. Lariviere WR, Melzack R. The role of corticotropinreleasing factor in pain and analgesia. Pain 2000; 84: 1-12.
14. Hargreaves KM, Flores CD, Mueller G. The role of pituitary b-endorphin in mediating CRF-induced antinociception. Amer J Physiol 1990; 258: E235-E242.
15. Kita A, Imano K, Nakamura H. Involvement of corticotropin-releasing factor in the antinociception produced by interleukin-1in mice. Eur J Pharmacol 1993; 237: 317-322.
16. Song ZH, Takemori AE. Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice. J Pharmacol Exp Ther 1990; 254: 363-368.
17. Bianchi M, Sacerdote P, Locatelli L, Mantegazza P, Panerai AE. Corticotropin-releasing hormone, interleukin-la, and tumor necrosis factor-a share characteristics of stress mediators. Brain Res 1991; 546: 139-142.
18. Cepeda MS, Bonney I, Moyano J, Carr DB. Corticotropin releasing hormone (CRH) produces analgesia in a thermal injury model independent of its effect on systemic betaendorphin and corticosterone. Regul Pept 2004; 118: 39-43.
19. Bianchi M, Panerai AE. CRH and the noradrenergic system mediate the antinociceptive effect of central interleukin-1 alpha in the rat. Brain Res Bull 1995; 36: 113-117.
20. Sawamura S, Obara M, Takeda K, Maze M, Hanaoka K. Corticotropin-releasing factor mediates the antinociceptive action of nitrous oxide in rats. Anesthesiology 2003; 99: 708-715.
21. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004; 18: 314-325.
22. Wingenfeld K, Heim C, Schmidt I, Wagner D, Meinlschmidt G, Hellhammer DH. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom Med 2008; 70: 65-72.
23. Hargreaves KM, Dubner R, Costello H. Corticotropin releasing factor (CRF) has a peripheral site of action antinociception. Eur J Pharmacol 1989; 170: 275-279.
24. Poree LR, Dickenson AH, Wei ET. Corticotropin-releasing factor inhibits the response of trigeminal neurons to noxious heat. Brain Res 1989; 502: 349-355.
25. Vit JP, Clauw DJ, Moallem T, Boudah A, Ohara PT, Jasmin L. Analgesia and hyperalgesia from CRF receptor modulation in the central nervous system of Fischer and Lewis rats. Pain 2006; 121: 241-260.
26. Pavcovich LA, Valentino RJ. Regulation of a putative neurotransmitter effect of corticotropin-releasing factor: effects of adrenalectomy. J Neurosci 1997; 17: 401-408.
27. Yarushkina NI, Bagaeva TR, Filaretova LP. Analgesic actions of corticotropin-releasing factor (CRF) on somatic pain sensitivity: involvement of glucocorticoids and CRF-2 receptors. Neurosci Behav Physiol 2009; 39: 819-823.
28. Ayesta FJ, Nikolarakis KE. Peripheral but not intracerebroventricular corticotropin-releasing hormone (CRH) produces antinociception which is not opioid mediated. Brain Res 1989; 503: 219-224.
29. Sherman J, Kalin N. ICV-CRH potently affects behavior without altering antinociceptive responding. Life Sci 1986; 39: 433-441.
30. Cui XY, Lundeberg T, Yu LC. Role of corticotropinreleasing factor and its receptor in nociceptive modulation in the central nucleus of amygdala in rats. Brain Res 2004; 995: 23-28.
31. Ji G, Neugebauer V. Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors. J Neurophysiol 2008; 99: 1201-1212.
32. Bogdanov AI, Yarushkina NI. The relationship between analgesia and corticosteroid levels in rats. Neurosci Behav Physiol 2000; 30: 487-489.
33. Bogdanov AI, Yarushkina NI. Mechanisms of the effects of adrenocorticotropic hormone on pain sensitivity in rats. Neurosci Behav Physiol 2003; 33: 795-798.
34. Lograsso M, Nadeson R, Goodchild CS. The spinal antinociceptive effects of cholinergic drugs in rats: receptor subtype specificity in different nociceptive tests. BMC Pharmacology 2002; 2: 20.
35. Wang QA, Mao LM, Han JS. Analgesia from electrical stimulation of the hypothalamic arcuate nucleus in pentobarbital-anesthetized rat. Brain Res 1990; 526: 221-227.
36. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 2010; 31: 98-132.
37. Filaretova L, Bagaeva T, Podvigina T, Makara G. Various ulcerogenic stimuli are potentiated by glucocorticoids deficiency in rats. J Physiology (Paris) 2001; 95: 59-65.
38. Bobryshev P, Bagaeva T, Filaretova L. Ischemic preconditioning attenuates gastric ischemia-reperfusion injury through involvement of glucocorticoids. J Physiol Pharm 2009; 60(Suppl. 7): 155-160.
39. Filaretova LP, Bagaeva TR, Makara GB. Aggravation of nonsteroidal anti-inflammatory drug gastropathy by glucocorticoid deficiency or blockade of glucocorticoid receptor in rats. Life Sci 2002; 71: 2457-2468.
40. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York, London, Academic Press, 1982.
41. Healy DL, Chrousos GP, Schulte NM, Gold PW, Hodgen GD. Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose response relationships. J Clin Endocrinol Metab 1985; 60: 1-4.
42. Bogdanov AI, Yarushkina NI. The role of the hormones of the hypothalamo-hypophyseal-adrenocortical system in the analgesic effect of corticotropin-releasing hormone. Neurosci Behav Physiol 2007; 37: 363-367.
43. McLennan AJ, Drugan R, Myson R, Maier S, Madden J, Barchas JD. Corticosterone: a critical factor in an opioid form of stress-induced analgesia. Science 1982; 215: 1530-1532.
44. Sutton LC, Fleshner M, Mazzeo R, Maier SF, Watkins LR. A permissive role of corticosterone in an opioid form of stressinduced analgesia: blockade of opiate analgesia is not due to stress-induced hormone release. Brain Res 1994; 663: 19-29.
45. Filaretova L, Morozova O, Bagaeva T, Podvigina T. From gastroprotective to proulcerogenic action of glucocorticoids on the gastric mucosa. J Physiol Pharmacol 2009; 60(Suppl. 7): 79-86.
46. Huo FQ, Qu CL, Li YQ, Tang JS, Jia H. GABAergic modulation is involved in the ventrolateral orbital cortex 5-HT 1A receptor activation-induced antinociception in the rat. Pain 2008; 139: 398-405.
47. Shin MS, Helmstetter FJ. Antinociception following application of DAMGO to the basolateral amygdala results from a direct interaction of DAMGO with mu opioid receptors in the amygdala. Brain Res 2005; 1064: 56-65.
48. Xiao DQ, Zhu JX, Tang JS, Jia H. 5-hydroxytryptamine 1A (5-HT1A) but not 5-HT3 receptor is involved in mediating the nucleus submedius 5-HT-evoked antinociception in the rat. Brain Res 2005; 1046: 38-44.
49. Fardin VJ, Oliveras JL, Besson JM. A reinvestigation of the analgesic effects induced by stimulation of periaqueductal gray matter in the rat: I. The production of behavioral side effects together with analgesia. Brain Res 1984; 306: 105-123.
50. Morgan A. Periaqueductal gray matter stimulation produced analgesia in pentobarbital anesthetized rat. Proc West Pharmacol Soc 1985; 28: 161-163.
51. Tortorici V, Aponte Y, Acevedo H, Nogueira L, Vanegas H. Tolerance to non-opioid analgesics in PAG involves unresponsiveness of medullary pain-modulating neurons in male rats. Eur J Neurosci 2009; 29: 1188-1196.
52. Filaretov A, Filaretova L. Role of the paraventricular and ventromedial hypothalamic nuclear areas in the regulation of the pituitary-adrenocortical system. Brain Res 1985; 342: 135-140.
53. Yirmiya R, Ben-Eliyahu S, Shavit Y, Marek P, Liebeskind JC. Stimulation of the hypothalamic paraventricular nucleus produces analgesia not mediated by vasopressin or endogenous opioids. Brain Res 1990; 537: 169-174.
54. Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-1112.
55. Yarushkina N. The role of hypothalamo-hypophysealadrenocortical system hormones in controlling pain sensitivity. Neurosci Behav Physiol 2008; 38: 759-766.